Antibody-drug conjugate

Daiichi to divest consumer health unit to Suntory for $1.5B

Fri, 17 Apr 2026 12:00:00 -0400

Daiichi Sankyo. Co. Ltd. will begin a phased sale of its consumer health subsidiary, Daiichi Sankyo Healthcare Co. Ltd., to Suntory Holdings Ltd., as the Tokyo-based drugmaker sharpens its focus on oncology.

FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC

Thu, 16 Apr 2026 12:00:00 -0400

The U.S. FDA has accepted and granted priority review to Daiichi Sankyo Co. Ltd. and Merck & Co. Inc.’s BLA of ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate (ADC) to treat patients with advanced extensive-stage small-cell lung cancer.

CSPC’s SYS-6051 cleared for clinic in China for solid tumors

Thu, 16 Apr 2026 09:00:00 -0400

CSPC Pharmaceutical Group Ltd.’s SYS-6051 has gained clinical trial clearance from China’s National Medical Products Administration (NMPA) for advanced solid tumors. SYS-6051 is a human tissue factor-targeted antibody-drug conjugate that binds to tissue factor expressed on the surface of tumor cells.

Glyconex’s GNX-1021 cleared for clinic in Japan for GI cancers

Wed, 15 Apr 2026 09:00:00 -0400

Glyconex Inc. has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the initiation of a first-in-human phase I trial of GNX-1021, the company’s lead antibody-drug conjugate (ADC) candidate, in patients with advanced gastrointestinal (GI) cancers.

Solve Therapeutics patents new anti-5T4 ADCs

Mon, 13 Apr 2026 09:00:00 -0400

Solve Therapeutics Inc. has disclosed new antibody-drug conjugates (ADCs) comprising antibody or antigen binding fragments targeting trophoblast glycoprotein (TPBG; 5T4) linked to a cytotoxic drug and therefore potentially useful for the treatment of cancer.

C4 yourself: $1B second Roche deal evidence of DAC faith

Thu, 09 Apr 2026 12:00:00 -0400

C4 Therapeutics Inc.’s degrader-antibody conjugate (DAC) strategy gathered more steam with a new collaboration between the firm and Roche AG that brings $20 million up front with the potential for more than $1 billion in discovery, regulatory and commercial milestone payments.

Sidewinder’s bispecific ADC approach draws $137M series B

Thu, 09 Apr 2026 09:00:00 -0400

Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027.

Sidewinder’s bispecific ADC approach draws $137M series B

Wed, 08 Apr 2026 12:00:00 -0400

Gilead buying Tubulis and its ADCs in $5B takeover bid

Tue, 07 Apr 2026 12:00:00 -0400

German company Tubulis GmbH, which emerged with a $12.3 million series A round and a next-generation antibody-drug conjugate (ADC) platform about six years ago, has commanded up to $5 billion in a buyout offer from Gilead Sciences Inc.

Five-drug VIPOR regimen shows promise in aggressive blood cancer

Tue, 07 Apr 2026 11:00:00 -0400

Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.

Stipple launches with $100M for novel oncology targets

Tue, 07 Apr 2026 09:00:00 -0400

Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform. The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest. Existing investors, including Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), Lola Capital Partners, GordonMD Global Investments and others, also participated in the round.

Next-generation anti-CD30 ADC outperforms brentuximab vedotin

Tue, 07 Apr 2026 09:00:00 -0400

Researchers from Mabqi SAS presented the preclinical profile of MQI-181, an antibody-drug conjugate (ADC) composed of a human anti-CD30 antibody (18D03) linked to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable MC-VC-PAB linker, with a drug-antibody ratio of 4.

Canwell gains IND clearance for ADC CAN-016

Tue, 07 Apr 2026 09:00:00 -0400

Canwell Pharma Inc. has obtained IND approval from the FDA for CAN-016, a novel antibody-drug conjugate (ADC). The company will initiate a phase I study in patients with HER2-expressing solid tumors who have experienced disease progression following prior ADC therapies.

Akari Therapeutics partners with Wuxi XDC on ADC payload

Tue, 07 Apr 2026 09:00:00 -0400

Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.

Stipple launches with $100M for novel oncology targets

Mon, 06 Apr 2026 12:00:00 -0400

New antibody-drug conjugates reported in Biocad patent

Thu, 02 Apr 2026 09:00:00 -0400

Biocad Ltd. has disclosed new antibody-drug conjugates consisting of antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.

Five-drug VIPOR regimen shows promise in aggressive blood cancer

Wed, 01 Apr 2026 12:00:00 -0400

Idel raises $10.4M for intracellular pan-cancer drug delivery tech

Thu, 26 Mar 2026 12:00:00 -0400

Newco Idel Therapeutics GmbH has closed a €9 million (US$10.4 million) seed round to advance the development of a technology for delivery of cytotoxic drugs directly into the cytosol of tumor cells.

Glyconex and Nippon Kayaku collaborate on GNX201-ADC

Tue, 24 Mar 2026 09:00:00 -0400

Glyconex Inc. has entered into a collaboration agreement with Nippon Kayaku Co. Ltd. to advance GNX201-ADC, a next-generation glycan-directed antibody-drug conjugate (ADC) candidate for the treatment of solid tumors.

Kelun-Biotech’s SKB-103 cleared to enter clinic in China

Tue, 24 Mar 2026 09:00:00 -0400

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has announced IND approval by China’s National Medical Products Administration (NMPA) for SKB-103 for the treatment of advanced solid tumors.

Henlius presents preclinical data on HLX-403

Wed, 18 Mar 2026 09:00:00 -0400

Shanghai Henlius Biotech Inc. has presented preclinical data on HLX-403, its novel anti-CDH17 antibody-drug conjugate (ADC), highlighting its potential for gastrointestinal cancers. A first-in-human trial is expected to commence in the third quarter of this year.

Kanaph’s $27M IPO to aid multi-modality cancer, immune portfolio

Tue, 17 Mar 2026 11:00:00 -0400

Multi-modality platform company Kanaph Therapeutics Inc. raised ₩40 billion (US$26.7 million) through its Kosdaq stock sale March 16, becoming the first Korean biotech to go public this year. The Seoul-based company’s shares (KOSDAQ:0082N0) climbed to ₩70,000 in intraday trading before closing at ₩50,600 – 153% higher than the offering price.

Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs

Tue, 17 Mar 2026 11:00:00 -0400

Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs.

Cytomx soars as early colorectal cancer data beat expectations

Mon, 16 Mar 2026 12:00:00 -0400

Shares of Cytomx Therapeutics Inc. hit a new 52-week high as the company unveiled preliminary data from an ongoing phase I study of varsetatug masetecan (Varseta-M) in late-line metastatic colorectal cancer.

Kanaph’s $27M IPO to aid multi-modality cancer, immune portfolio

Mon, 16 Mar 2026 12:00:00 -0400

Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs

Fri, 13 Mar 2026 12:00:00 -0400

Valanx Biotech secures funding to advance LIV-1-targeted ADC

Thu, 12 Mar 2026 09:00:00 -0400

Valanx Biotech Gmbh has secured €3 million (US$4 million) in funding to advance its lead antibody-drug conjugate (ADC) program. The financing will enable preclinical development of VLX-ADC-001.

Shanghai Chempartner describes new ADCs targeting HER2 and TROP2

Mon, 09 Mar 2026 09:00:00 -0400

Shanghai Chempartner Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising HER2 (erbB2) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to eribulin through a linker reported to be useful for the treatment of cancer.

Systimmune’s iza-bren hits phase III breast cancer goals in China

Tue, 03 Mar 2026 12:00:00 -0500

In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.

Next-generation dual-payload ADCs advance in oncology pipelines

Mon, 02 Mar 2026 08:00:00 -0500

Researchers from Sutro Biopharma Inc. presented data on dual-payload antibody-drug conjugates (ADCs) engineered to overcome drug resistance, demonstrating enhanced cytotoxicity and potential efficacy in resistant cancer models.